High expression of LMO2 in Hodgkin, Burkitt and germinal center diffuse large B cell lymphomas

Journal of the Egyptian National Cancer Institute

Volumn 23, Issue 4, 2011, Pages 147-153

  Shams, Tahany M ^a  

^a Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Burkitt lymphoma; Diffuse large B cell; Hodgkin lymphoma; Immunostaining; LMO2; Lymphomas

Indexed keywords

LIM PROTEIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER STAGING; CHILD; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GERMINAL CENTER; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; BURKITT LYMPHOMA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GERMINAL CENTER; HODGKIN DISEASE; HUMANS; KI-67 ANTIGEN; LIM DOMAIN PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; YOUNG ADULT;

EID: 84890538549     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2011.10.006     Document Type: Article

References (29)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics. CA Cancer J Clin 2010, 55:10-30.
2. Mokhtar N, Gouda I, Adel I. Cancer pathology registry 2003-2004 and time trend analysis. 2007, p. 24-39 [chapter 3].
3. Shipp M.A., Ross K.N., Tamayo P., Tamayo P., Weng A.P., Kutok J.L., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
4. Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003, 100:9991-9996.
5. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
6. Barrans S.L., Carter I., Owen R.G., Davies F.E., Patmore R.D., Haynes A.P., et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002, 99:1136-1143.
7. Colomo L., Lopez-Guillermo A., Perales M., Rives S., Martínez A., Bosch F., et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003, 101:78-84.
8. Linderoth J., Jerkeman M., Cavallin-Stahl E., Kvaloy S., Torlakovic E. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res 2003, 9:722-728.
9. McClintock S, Perkins SL, Cleveland RP, Trzpuc T, Vesole DH, Logan B, et al. Immunohistochemical expression pattern of germinal center and activation B-cell markers correlates with prognosis in diffuse large B-cell lymphoma [abstract]. Mod Pathol 2003;16:244a.
10. Yamada Y., Warren A.J., Dobson C., Forster A., Pannell R., Rabbitts T.H. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 1998, 95(7):3890-3895.
11. Natkunam Y., Zhao S., Mason D.Y., Chen J., Taidi B., Jones M., et al. The oncoprotein LMO2 is expressed in normal germinal center B cells and in human B-cell lymphomas. Blood 2007, 109(4):1636-1642.
12. Jaffe ES, Harris NL, Vardiman JW. Pathology and Genetics. Tumors of hematopoietic and lymphoid tissues. WHO Classification of Tumors, 2001.
13. Nakamura N., Nakamine H., Tamaru J.I., Nakamura S.H., Nakamura Sh., Yoshino T., et al. The distinction between Burkitt lymphoma and diffuse large B cell lymphoma with C-myc rearrangement. Mod pathol 2002, 15(7):771-776.
14. Falini B., Fizzotti M., Pucciarini A., Bigerna B., Marafioti T., Gambacorta M., et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000, 95:2084-2092.
15. Dogan A., Bagdi E., Munson P., Isaacson P.G. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000, 24:846-852.
16. Falini B., Mason D.Y. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002, 99:409-426.
17. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-Cell lymphoma. NEJM 2002, 346:1937-1947.
18. Warren A.J., Colledge W.H., Carlton M.B., Evans M.J., Smith A.J., Rabbitts T.H. The oncogenic cysteine rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994, 78:45-57.
19. Yamada Y., Pannell R., Forster A., Rabbitts T.H. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci USA 2000, 97:320-324.
20. Bach I. The LIM domain: regulation by association. Mech Dev 2000, 91:5-17.
21. Kuppers R., Rajewsky K., Zhao M., et al. Hodgkin disease: Hodgkin and Reed Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B calls at varies stages of development. Proc Natl Acad Sci USA 1994, 91:1092-1096.
22. Kanzler H., Kuppers R., Hansmann M.L., Rajewsky K. Hodgkin and Reed Sternberg cells in Hodgikins disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996, 184:1495-1505.
23. Swerdlow SH, Campo E, Harris NL. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon, France: IARC Press 2008, 4th ed: 233-237.
24. Klein U., Tu Y., Stolovitzky G.A., Keller J.L., Haddad J., Miljkovic V., et al. Gene expression dynamics during germinal center transit in B cells. Ann NY Acad Sci 2003, 987:166-172.
25. Stamatopoulos K., Belessi C., Papadaki T., Stavroyianni N., Hadzidimitriou A., Kosmas C., et al. Somatic hypermutation patterns in germinal center B cell malignancies. Hematology 2003, 8:319-328.
26. Kuppers R. Identifying the precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease: Role of the germinal center in B-cell lymphomagenesis. J Acquir Immune Defic Syndr 1999, 21:S74-S79.
27. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
28. Natkunam Y., Farinha P., Hsi E.D., Hans Ch., Tibshirani R., Sehn L.H., et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008, 26:447-454.
29. Lossos I.S., Czerwinski D.K., Alizadeh A.A., Wechser M.A., Tibshirani R., Botstein D., et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350:1828-1837.